Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology by Chi Chiu Mok et al.
REVIEW ARTICLE
Management of rheumatoid arthritis: consensus
recommendations from the Hong Kong Society
of Rheumatology
Chi Chiu Mok & Lai Shan Tam & Tak Hin Chan &
Gavin K. W. Lee & Edmund K. M. Li &
Hong Kong Society of Rheumatology
Received: 29 September 2010 /Accepted: 29 September 2010 /Published online: 3 November 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Given the recent availability of novel biologic
agents for the treatment of rheumatoid arthritis (RA), the
Hong Kong Society of Rheumatology has developed
consensus recommendations on the management of RA,
which aim at providing guidance to local physicians on
appropriate, literature-based management of this condition,
specifically on the indications and monitoring of the biologic
disease-modifying anti-rheumatic drugs (DMARDs). The
recommendations were developed using the European
League Against Rheumatism (EULAR) recommendations
for the management of early arthritis as a guide, along with
local expert opinion. As significant joint damage occurs
early in the course of RA, initiating therapy early is key to
minimizing further damage and disability. Patients with
serious disease or poor prognosis should receive early,
aggressive therapy. Because of its good efficacy and safety
profile, methotrexate is considered the standard first-line
DMARD for most treatment-naïve RA patients. Patients
with a suboptimal response to methotrexate monotherapy
should receive step-up (combination) therapy with either the
synthetic or biologic DMARDs. In recent years, combina-
tions of methotrexate with tocilizumab, abatacept, or
rituximab have emerged as effective therapies in patients
who are unresponsive to traditional DMARDs or the anti-
tumor necrosis factor (TNF)-α agents. As biologic agents
can increase the risk of infections such as tuberculosis and
reactivation of viral hepatitis, screening for the presence of
latent tuberculosis and chronic viral hepatitis carrier state is
recommended before initiating therapy.
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Introduction
Rheumatoid arthritis (RA) is a chronic, autoimmune,
systemic, inflammatory disease mainly affecting the joints
characterized by pain, swelling, and stiffness, resulting in
progressive joint destruction, deformity, and loss of
function. In addition to articular symptoms, other organ
systems may also be involved. RA affects approximately
0.5% to 1% of the adult population in the developed world
[1]. It is less prevalent in mainland China and in Hong
Kong, with a reported prevalence of 0.37% and 0.35%,
respectively [2, 3].
Although the etiology of RA remains largely unknown,
both genetic and nongenetic causes have been implicated.
Inflammation is initially localized in the synovial lining
where there is synovial cell proliferation (pannus forma-
tion) and infiltration by inflammatory cells. The pannus
invades and destroys cartilage and bone, leading to
irreversible joint destruction and deformity [4]. Erosions
of the feet joints on extremity magnetic resonance imaging
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(MRI) are found in up to 91% of patients early in the course
of the disease [5]. Therefore, early diagnosis and treatment
are crucial for preventing further joint damage. Currently,
the classification of RA is based on the 1987 American
College of Rheumatology (ACR) clinical classification
criteria using history, physical examination, and laboratory
and radiographic findings [6]; this set of criteria has been
criticized for lack of sensitivity in early disease. A new set
of joint ACR-European League Against Rheumatism
(EULAR) criteria for RA classification has recently been
published [7].
The goals of treatment of RA are to alleviate symptoms,
slow or stop disease progression, and reduce disability. The
current RA treatment armamentarium comprises both
synthetic and biologic disease-modifying anti-rheumatic
drugs (DMARDs).
In 2005, the Hong Kong Society of Rheumatology
(HKSR) published consensus recommendations on the use
of anti-tumor necrosis factor (TNF)-α agents in the
treatment of RA, ankylosing spondylitis, and psoriatic
arthritis [8]. However, consensus recommendations on
overall RA management had yet to be developed. Given
the availability of newer biologic agents for RA treatment,
the HKSR initiated the development of these consensus
recommendations, which are aimed at providing guidance
to Hong Kong physicians on appropriate, literature-based
management of this condition, specifically on the indica-
tions and monitoring of the novel biologic DMARDs.
Methods
The consensus recommendations were developed using the
EULAR recommendations for the management of early
arthritis [9] as a guide, along with local expert opinion.
Clinical evidence supporting these recommendations were
categorized as to level of evidence based on the classifica-
tion system in Table 1.
Results
Panel recommendations on RA management
Recommendation 1: General principles
Early RA treatment improves the rate of clinical
response and ultimate outcome. Early, aggressive
therapy is required for patients with serious disease
and/or poor prognostic factors. Treatment must be
individualized, based on physicians' and patients'
preference, and medical contraindications, among
others.
Evidence from published clinical trials shows better
outcomes in early arthritis when treatment is initiated early;
considerably more radiographic damage occurs when
therapy is delayed (category A) [9–11]. In patients with
more severe disease, it is important to achieve and maintain
low disease activity as early as possible to prevent
structural damage, thus necessitating a more intense
treatment approach. Clinical trial data show that initial
intensive treatment produces better outcomes than mono-
therapy in early arthritis (category A) [9, 12–14]. However,
it is important to bear in mind that, given the variety of
available treatments and the heterogeneity of patients, the
management strategy should ultimately be tailored to the
individual patient, taking into account factors such as
individual preferences, contraindications, and side effects.
Recommendation 2: Patient assessment
(a) Anti-cyclic citrullinated peptide (anti-CCP) anti-
body testing, ultrasound, and MRI may be
utilized in the early diagnosis of RA. These tests
are not recommended as routine tests but should
be used for specific indications only.
Anti-CCP testing may help establish an early diagnosis
in patients who do not fulfill the 1987 ACR criteria, or for
atypical cases. The anti-CCP antibodies have been shown
to be more specific than the rheumatoid factor (RF) for
diagnosing RA and possibly better predict radiographic
progression of joint erosion (category C) [15]; anti-CCP
testing has been incorporated into the new EULAR
classification criteria to enhance its specificity for early
disease [7]. Ultrasound and MRI are suitable for early
diagnosis of bony erosions in patients who do not fulfill
the 1987 ACR criteria, or as a guide for joint aspiration
and injection in difficult cases. Both these imaging techniques
are more sensitive than radiography for detecting cartilage and
bone abnormalities and can even identify earlier stages of the
disease (category B) [16, 17]. However, despite their benefits
in early diagnosis of RA, these imaging techniques and
testing for anti-CCP antibodies are significantly more costly
and, therefore, should not be used routinely for every patient
who presents with joint symptoms.
(b) Disease Activity Score using 28 joint counts
(DAS28) should be utilized in the assessment of
RA disease activity. Clinicians should try to
compute the DAS28 at regular intervals, prefer-
ably during each clinic visit.
High disease activity (HDA): DAS28>5.1
Moderate disease activity (MDA): DAS28=3.2–5.1
Low disease activity (LDA): DAS28=2.6–3.2
Remission: DAS28<2.6
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The DAS28 is a useful instrument in clinical practice for
objectively evaluating disease progression and response to
therapy (category B) [18]. It includes four variables: (1)
number of tender joints from among 28 joints, (2) number
of swollen joints from among 28 joints, (3) erythrocyte
sedimentation rate (ESR), and (4) patient's assessment of
general health status. C-reactive protein (CRP) may be used
as an alternative to ESR in the calculation of the DAS28
score, using predetermined formulas (category B) [19]. The
DAS28 score ranges from 0 to 9.4 and can be used to
readily classify disease activity levels into high, moderate,
low, and remission.
(c) Factors indicating an unfavorable prognosis of
RA include chronic smoking, high titres of anti-CCP
or RF, radiologic erosion at onset, positive family
history, HDA, severe functional limitation, and extra-
articular manifestations (e.g., rheumatoid nodules).
Several prognostic factors have been linked with a worse
outcome in RA. Numerous reports exist of a relationship
between smoking and increased severity of RA (category
C) [20, 21]. The presence of anti-CCP antibodies is a strong
predictor of radiological damage and progression (category
C) [22]. In addition, HDA at baseline [23], RF [23],
radiologic damage at disease onset [24], and presence of
extra-articular manifestations [25] are also predictors of poor
outcome (category C). The ACR 2008 recommendations
further confirm these prognostic factors as commonly used
clinically important predictors of poor RA outcome [26].
(d) Clinicians should regularly assess the extent of
their patients' disability and functional capacity.
Possible assessment tools include the Health Assess-
ment Questionnaire (HAQ) and the Medical Out-
comes Study short-form health survey (SF-36).
Since improving disability, function, and health-related
quality of life are important goals for patients, regular
assessments of these should become an integral part of RA
management. The commonly used assessment tools, the
HAQ and SF-36, assess the impact of disease in terms of
patient-centered outcomes [27]. The HAQ, the most
commonly used health status measure, primarily determines
functional disability, while the SF-36 assesses limitations in
physical activities, as well as emotional status of patients.
Recommendation 3: Treatment
(a) The goal of treatment is disease remission (i.e.,
DAS28<2.6), regardless of whether the patient has
early or established RA. It should be emphasized that
treatment of early RA results in better response rates
and a higher probability of drug-free remission.
Since there is no cure for RA, remission has become the
accepted treatment goal to arrest joint damage and reduce
the likelihood of long-term disability (category B) [9, 11].
Clinical trials of both early [12–14] and established [28]
RA have demonstrated better remission rates and radio-
graphic progression with early intensive treatment than
monotherapy or routine care (category A).
(b) Treatment with synthetic DMARDs should be
initiated as soon as possible after a diagnosis of RA is
made. DMARD-naïve patients should be started on
methotrexate monotherapy. Methotrexate should be
given for a duration of no less than 3 months at the
maximally tolerated dose. Patients without poor prog-
nostic factors (i.e., with no erosions, are RF-negative,
with low CRP levels, or with low disease activity) or
those who cannot tolerate methotrexate may receive
other DMARDs, such as leflunomide, sulfasalazine,
hydroxychloroquine, or injectable gold. Corticoste-
roids, given orally, intramuscularly, or intra-articularly,
may be used as bridging therapy as appropriate. A
combination of DMARDs, or methotrexate combined
with an anti-TNF-α agent, may be considered in
patients with very serious disease and poor prognostic
factors. However, the cost-effectiveness of the latter
approach has yet to be determined.
Several clinical trials have clearly established the short-
and long-term efficacy and the relatively beneficial safety
profile of methotrexate in RA (category A) [9, 29, 30].
Category A At least one RCT or meta-analyses of RCTs, or reviews if these contain
category A references
Category B At least one controlled trial without randomization or at least one other
type of experimental study, or extrapolated recommendations
from RCTs or meta-analyses
Category C Non-experimental descriptive studies, such as comparative studies,
correlational studies, and case-control studies, which are extrapolated
from RCTs, non-randomized controlled studies, or other
experimental studies
Category D Expert committee reports or opinions or clinical experience of
respected authorities.
Also includes all abstracts
Table 1 Strength of clinical
evidence
RCT randomized control trial
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Methotrexate is considered the “anchor drug,” and there is
widespread acceptance for its use as initial therapy in most
RA patients (category A) [9, 31, 32]. Alternative first-line
treatments include sulfasalazine, which shows similar
efficacy to methotrexate, and hydroxychloroquine, which
has very good tolerability among the DMARDs (category
B) [11, 26, 33]. Combination treatment with two or more
DMARDs, or of methotrexate and an anti-TNF-α agent,
has been shown to confer greater efficacy than monother-
apy and, thus, is appropriate for patients with serious
disease or poor prognostic factors (category A) [9, 12, 13,
34–36]. However, the cost-effectiveness of first-line inter-
vention with biologic agents in treatment-naïve patients
remains uncertain (category C) [37].
(c) Suboptimal treatment response is defined as
failure to achieve remission (i.e., DAS28<2.6) after
3 months of methotrexate at a dose of at least 15 mg/
week. Such patients (i.e., DAS28≥2.6 despite meth-
otrexate) should receive step-up therapy, i.e., combi-
nation therapy of methotrexate plus another agent:
methotrexate plus leflunomide, methotrexate plus
sulfasalazine plus hydroxychloroquine, or methotrex-
ate plus a biologic agent.
For patients who continue to present with active disease
despite methotrexate, addition of another conventional
DMARD or biologic agent should be considered (category
A) [9, 11, 26]. In one randomized, placebo-controlled trial,
the addition of leflunomide to existing methotrexate therapy
resulted in significant clinical benefit in patients with
persistently active RA (category A) [38]; however, given
the recent FDA report of fulminant hepatitis in leflunomide
users, meticulous monitoring of liver function is warranted
in patients administered this drug [39]. In another random-
ized trial, combination therapy with methotrexate, sulfasa-
lazine, and hydroxychloroquine resulted in better remission
rates than single treatment in early RA (category A) [40].
Similarly, other randomized controlled trials have demon-
strated better clinical efficacy when TNF-α inhibitors
(etanercept, adalimumab, and infliximab) were given
concomitant with methotrexate, following inadequate re-
sponse to methotrexate alone (category A) [41–43]. The
ACR 2008 recommendations suggest a variety of dual and
triple drug combinations, incorporating methotrexate,
depending on the patient's level of disease activity, disease
duration, and prognostic features (category B) [26].
(d) Patients who require methotrexate plus a biologic
agent may be administered any one of the following
combinations: methotrexate plus an anti-TNF-α
agent, methotrexate plus tocilizumab, methotrexate
plus abatacept, or methotrexate plus rituximab. The
choice of biologic will depend on various factors,
including patient's and physician's preferences, avail-
ability of funding, and medical history.
The value of the combination of methotrexate and anti-
TNF-α agents in improving radiographic, clinical, and
functional outcomes is well established (category A) [12,
13, 36, 41–43]. In recent years, several novel biologic drugs
with different mechanisms of action have emerged as
potential additions to rheumatologic pharmacotherapy.
These include the interleukin (IL)-6 inhibitor tocilizumab,
the selective T-cell co-stimulation modulator abatacept, and
the chimeric, anti-CD20 monoclonal antibody rituximab.
Several recent randomized, double-blind, placebo-
controlled trials have demonstrated superior therapeutic
efficacy when each of these agents was co-administered
with methotrexate in RA patients [44–51].
Trials involving tocilizumab have shown decreased disease
activity and better remission rates (category A) [44–46]. One
trial showed tocilizumab monotherapy to be superior to
methotrexate monotherapy in DMARD/methotrexate-naïve
patients (category A) [47]; another demonstrated that
tocilizumab with methotrexate delayed radiographic progres-
sion of structural joint damage significantly more than
methotrexate alone in patients who respond inadequately to
methotrexate (category A) [48]. A clinical trial using
abatacept demonstrated improvements in arthritis signs and
symptoms, physical function, and quality of life at 1 year
[49], and inhibition of radiological progression for up to
2 years (category A) [50]. Another clinical trial of rituximab
showed improvements in disease activity, fatigue, disability,
and health-related quality of life (category A) [51].
(e) Anti-TNFα failure patients (failure of DAS28 to
improve by 1.2 or <5.1 over 16 weeks) may be
administered any one of the following: another anti-
TNF-α agent, tocilizumab, abatacept, or rituximab.
There is less evidence to support the efficacy of
rituximab in seronegative RA patients.
Despite their efficacy in RA, anti-TNF-α agents elicit an
inadequate response in a substantial number of patients. In
such patients, alternative biologic agents are recommended.
Evidence shows that patients who are refractory to anti-
TNF-α therapy gain significant clinical and functional
benefits from tocilizumab [44], rituximab [51], or abatacept
(category A) [52]. However, rituximab may not be equally
efficacious in all RA patients. A recent pooled analysis of
two-phase III rituximab trials has shown that patients who
are seropositive (anti-RF and anti-CCP positive) are
significantly more likely to achieve a clinical response than
those who are seronegative (category A) [53]. These
findings suggest that the serological status of patients
should be taken into consideration when choosing these
biologic agents.
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Recommendation 4: Safety considerations
(a) Prior to using a biologic agent, the clinician should
screen the patient for both active and latent tuberculosis
infection. Patients with active tuberculosis should be
adequately treated with the standard regimen before
reconsideration of biologic treatment. Patients who
screen positive for latent tuberculosis infection (i.e., with
a positive purified protein derivative (PPD) test, defined
as an induration of ≥10mm in diameter) should be given
isoniazid treatment for 9 months. If the indication for
biologic use is not urgent, isoniazid should be given for
4 weeks, to assess tolerability, before administration of
the biologic agent. For patients who test PPD-negative,
there is insufficient evidence to recommend annual
retesting unless there is recent exposure to tuberculosis
or the risk of transmission is high.
Numerous reports indicate an increased risk of developing
active tuberculosis soon after initiating anti-TNF-α agents
(category A) [54]. Furthermore, in patients with a past
history of tuberculosis, abatacept treatment may reactivate
the infection as it is known to compromise T-cell immunity.
This has led to the recommendation for routine screening for
active and latent tuberculosis infection whenever treatment
with these biologic agents is considered (category D) [54,
55]. While an induration of ≥10 mm in diameter has been
determined to be appropriate to signify a positive PPD test
for patients with RA, a lower cut-off of ≥5 mm has been
utilized to define latent tuberculosis in patients who are
significantly immunocompromised, such as those with
human immunodeficiency virus (HIV) infection or who are
transplant recipients (category D) [55]. Patients with evi-
dence of latent tuberculosis infection should receive prophy-
lactic tuberculosis treatment with isoniazid for 9 months
before commencing biologic agents (category B) [54, 55].
Rifampicin as monotherapy for 4 months is recommended
for patients resistant to, or intolerant of, isoniazid, or for
whom isoniazid is contraindicated (category D) [55].
(b) In addition, the hepatitis B and C status of
patients should be screened. Chronic carriage of
hepatitis B and C virus (HBV and HCV, respective-
ly) is a relative contraindication for the use of anti-
TNF-α agents. Active hepatitis has to be excluded
and baseline HBV DNA or HCV RNA levels should
be checked for chronic carriers of HBV and HCV.
Appropriate antiviral therapy, as determined by the
co-managing hepatologist, is indicated. Patients
should be warned of the risk of fulminant hepatitis
reactivation. Rituximab is contraindicated in chronic
hepatitis B or C carriers. There is little information
regarding the safety of tocilizumab and abatacept in
chronic viral hepatitis carriers.
Another important safety consideration when making
therapeutic decisions with biologics is hepatitis B and C
status. The anti-TNF-α agents are relatively contraindicated in
carriers of HBV and HCV because of reports of viral
reactivation, which can lead to serious complications (category
B) [26, 56, 57]. If there are no alternatives, patients should be
warned of the risk of serious hepatitis reactivation prior to
administration of an anti-TNF-α agent. In clinical trials of
hemic malignancies, rituximab has been shown to reactivate
occult hepatitis B (i.e., HBsAg-negative but anti-HBc-IgG-
positive) [58, 59]; it is, therefore, contraindicated in chronic
hepatitis B carriers and in patients with past hepatitis B
infection. Hence, all candidate patients for these drugs should
be screened for HBVand HCV infections before commencing
treatment. In particular, the status of both HBsAg and anti-
HBc-IgG should be determined before rituximab treatment.
There is insufficient information on the safety of tocilizumab
and abatacept in chronic viral hepatitis carriers.
(c) History of solid tumor is not a contraindication for
use of anti-TNF-α agents if there is no recurrence in the
past 5 years. Anti-TNF-α agents should be avoided in
patients with a history of lymphoproliferative disorders.
Although etanercept has been associated with an increased
incidence of solid malignancies in one clinical trial (category
A) [60], anti-TNF-α therapy is generally not associated with
an increased occurrence of solid tumors. According to a
Swedish population-based study, the relative risks of solid
cancers in anti-TNF-α treated patients were similar to those
of other RA patients (category C) [61]. Hence, anti-TNF-α
agents are not contraindicated in patients with solid tumor
history if there is no recurrence in the past 5 years.
However, they should be avoided in patients with prior
lymphoproliferative disorders because of significantly in-
creased risk of lymphomas (category C) [26, 62].
(d) Use of anti-TNF-α agents is contraindicated in
patients with severe heart failure, demyelinating
disorders, or lupus-like features.
Treatment of moderate-to-severe heart failure patients
with anti-TNF-α agents has been associated with either no
clinical benefit [63] or worsening of heart failure outcomes
[64] (category A). Furthermore, these agents are known to
induce autoimmune diseases such as demyelinating disor-
ders and lupus and, as such, should be avoided in patients
with these underlying conditions (category B) [26, 65].
(e) Live attenuated vaccines are not recommended
for patients being treated with biologic agents. Killed
vaccines (e.g., influenza vaccine, pneumococcal vac-
cine), if required, should be given prior to adminis-
tration of biologic agent.
Clin Rheumatol (2011) 30:303–312 307
Because the level of immune response to vaccinations
may be impaired, live vaccines are contraindicated during
biologic therapy (category D) [26]. Alternatively, inacti-
vated vaccines can be safely administered, typically at least
2 to 4 weeks, before initiating biologic therapy.
(f) Patients on biologic agents should be closely
monitored for side effects.
Patients should be very closely monitored for
infective complications, including opportunistic
infections.
Patients should be monitored for symptoms of
tuberculosis infection, both within and outside the
respiratory system. Chest X-ray should be per-
formed every 3 months during the first year of
therapy and annually thereafter, or when the patient
develops symptoms.
Complete blood count, renal/liver function tests,
lymphocyte count (for rituximab), and neutrophil
count (for tocilizumab) should be regularly checked.
Fasting lipid levels should be regularly surveyed
(particularly for tocilizumab) and statins should be
given whenever appropriate.
Look out for new neurological symptoms in
patients administered rituximab.
Look out for gastrointestinal symptoms in patients
administered tocilizumab, especially those with a
history of diverticulitis or intestinal ulceration.
Adverse events, especially serious adverse events,
should be reported to the HKSR Biologics Registry.
Registries and databases have reported an increased risk
of serious bacterial infections with the use of biologic
DMARDs (category A) [66–68]. In particular, the rates of
pneumonia and serious skin and soft tissue infections are
increased. Once biologic therapy is initiated, patients
should, therefore, undergo regular safety assessments.
Chest X-rays should be performed to detect possible
reactivation of latent tuberculosis. Laboratory testing,
including lymphocyte count for rituximab and neutrophil
count for tocilizumab, are warranted as treatment with each
Table 2 Panel recommendations on RA management—summary
Recommendation 1: General principles
Early RA treatment improves the outcome. Early, aggressive therapy is indicated for patients with serious disease and/or poor prognostic factors
Recommendation 2: Patient assessment
(a) Anti-CCP antibody testing, ultrasound and MRI may be utilized to aid early diagnosis of RA but they are not recommended for routine use
(b) DAS 28 should be utilized in the assessment of RA disease activity. Clinicians should try to compute the DAS28 at regular intervals
(c) Factors indicating an unfavorable prognosis of RA include chronic smoking, high titres of anti-CCP or RF, radiologic erosion at onset,
positive family history, HDA, severe functional limitation, and extra-articular manifestations (e.g., rheumatoid nodules)
(d) Clinicians should regularly assess the extent of their patients' disability and functional capacity
Recommendation 3: Treatment
(a) The goal of treatment is disease remission (i.e., DAS28<2.6)
(b) Treatment with synthetic DMARDs should be initiated as soon as possible after a diagnosis of RA is made. DMARD-naïve patients should be
started on MTX monotherapy. A combination of DMARDs, or MTX combined with an anti-TNF-α agent, may be considered in patients with
very serious disease and poor prognostic factors
(c) Suboptimal treatment response is defined as failure to achieve remission after 3 months of MTX at its maximally tolerated dose. Such patients
should receive step-up therapy, i.e., combination therapy of MTX plus another agent (e.g., LEF, SSz/HCQ, biologic agent)
(d) Patients who require MTX plus a biologic agent may be administered any one of the following combinations: MTX plus an anti-TNF-α
agent, tocilizumab, abatacept, or rituximab
(e) Anti-TNF therapy failure patients may be administered another anti-TNF-α agent, tocilizumab, abatacept or rituximab
Recommendation 4: Safety considerations
(a) Prior to using a biologic agent, patients should be screened for tuberculosis infection. Patients with active tuberculosis should be adequately
treated before reconsideration of biologic treatment. Patients who screen positive for latent tuberculosis infection receive isoniazid treatment for
9 months
(b) The hepatitis B and C status of patients should be screened. Active hepatitis has to be excluded and baseline HBV DNA or HCV RNA levels
should be checked for chronic carriers. Appropriate antiviral therapy is indicated. Patients should be warned of the risk of fulminant hepatitis
reactivation. Rituximab is contraindicated in chronic hepatitis B or C carriers
(c) Patients should be regularly monitored for side effects. Investigations such as chest radiograph, complete blood counts, lymphocyte count,
liver and renal function tests, and lipid level should be assessed at regular intervals
Recommendation 5: Cardiovascular risk factors and bone mineral density
Patients with RA should be screened for risk factors for CV disease and for osteoporosis. Once detected, these conditions should be managed as
appropriate
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of these agents is associated with rapid depletion of
peripheral B-cells [51] and neutropenia [44–46, 69],
respectively (category A). Treatment with biologic agents,
particularly tocilizumab, can alter the serum lipid profile,
resulting in increased low density lipoprotein (LDL), and
total cholesterol levels (category B) [70]. Hence, it is
important to monitor lipid levels and administer statin
therapy, when required. Tocilizumab administration has
been associated with bowel perforation and subsequent
peritonitis [69] and, therefore, should be closely monitored
in patients with a history of diverticulitis or intestinal
ulceration (category B). Testing of laboratory safety
parameters should be performed regularly.
Recommendation 5: Cardiovascular risk factors and
bone mineral density
Patients with RA should be screened for risk factors
for cardiovascular (CV) disease and for osteoporosis.
Once detected, these conditions should be managed as
appropriate.
RA patients are more prone to CV disease: the
standardized incidence ratio of myocardial infarction and
stroke is 1.5 to 1.7 times that of the incidence in the general
population (category A) [71–74]. This is attributable to an
increased prevalence of traditional CV risk factors and
persistent elevation of inflammatory cytokines in this
population. Early identification, adequate management,
and ongoing monitoring of risk factors are necessary to
reduce this excess CV risk. The latest EULAR recom-
mendations for CV risk management in patients with RA
and other forms of inflammatory arthritis states that the
first principle of management is to assess and control all
components of total CV risk, which includes providing
appropriate, evidenced-based advice with regard to
smoking, physical activity, diet, weight, and blood
pressure, as well as aggressive suppression of the
inflammatory process to further lower risk (category D)
[75]. Similarly, RA patients are more likely to develop
osteoporosis and fragility fractures (category A) [76].
Appropriate screening, monitoring and therapy for osteo-
porosis is deemed mandatory.
Conclusion
These recommendations by the HKSR summarize the latest
evidence pertaining to RA management (Table 2), with a
focus on the use of novel, biologic DMARDs. While
methotrexate is still held up as the primary therapeutic
option for most RA patients, new biologic agents currently
available are recognized as effective and safe treatment
modalities, particularly in patients with a suboptimal
response to traditional DMARDs. Given that most of these
biologics have only very recently come into use, and that
they been associated with the development of infective and
other complications, these recommendations emphasize the
importance of vigilant monitoring for side effects, notably
serious bacterial and viral infections, in patients adminis-
tered these agents.
These recommendations will be reviewed periodically, in
light of new published evidence and adverse event reports.
As these recommendations evolve and gradually become
more explicit, they will provide even more specific guidance
to rheumatologists and other physicians who treat patients
with RA, ultimately leading to improved clinical outcomes.
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